Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial

Autor: Platzbecker, Uwe *, Middeke, Jan Moritz, Sockel, Katja, Herbst, Regina, Wolf, Dominik, Baldus, Claudia D, Oelschlägel, Uta, Mütherig, Anke, Fransecky, Lars, Noppeney, Richard, Bug, Gesine, Götze, Katharina S, Krämer, Alwin, Bochtler, Tilmann, Stelljes, Matthias, Groth, Christoph, Schubert, Antje, Mende, Marika, Stölzel, Friedrich, Borkmann, Christine, Kubasch, Anne Sophie, von Bonin, Malte, Serve, Hubert, Hänel, Mathias, Dührsen, Ulrich, Schetelig, Johannes, Röllig, Christoph, Kramer, Michael, Ehninger, Gerhard, Bornhäuser, Martin, Thiede, Christian
Zdroj: In The Lancet Oncology December 2018 19(12):1668-1679
Databáze: ScienceDirect